DPP4 and diabetic kidney disease: A single-arm, open-label, observational study showed that switching to teneligliptin from other DPP-4 inhibitors for 24 weeks reduced the plasma DPP-4 activity, which was associated with a reduction in albuminuria, independent of the glucose-lowering effects, in T2D patients with early-stage DKD [121].